Evidence map›Paper›PMID 40552817›Full record

ArticleJournal of virology2025

CD317 functions as a key antiviral factor in human herpesvirus 6 (HHV-6) infection.

Xianyi Xu, Minmin Song, Xin Zhang, Junli Jia, Shuhua Chen, Hua Xie, Lingyun Li, Jingjing Ma, Huamin Tang

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xianyi Xu *Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
Minmin Song *Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
Xin ZhangDepartment of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
Junli JiaDepartment of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
Shuhua ChenDepartment of Critical Care Medicine, Changzhou Cancer Hospital, Changzhou, China.
Hua XieJintan Hospital Affiliated to Jiangsu University, Changzhou, China.
Lingyun LiDepartment of Medical Genetics, Nanjing Medical University, Nanjing, China.
Jingjing MaDepartment of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-2548-5871
Huamin TangDepartment of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-5724-3973

Funding

National Natural Science Foundation of China 32070945National Natural Science Foundation of China 32470153National Natural Science Foundation of China 82172263Natural Science Foundation of Jiangsu Province BK20231262the Nanjing special Fund for Health Science and Technology Development Program of China YKK21154 2021
6 · The paper itself

Abstract

CD317, an interferon-stimulated gene, is known for its role in inhibiting the release of various enveloped viruses from infected cells. However, its function can vary, as it also promotes infection in certain contexts, such as with human cytomegalovirus (HCMV). Human herpesvirus 6 (HHV-6) and HCMV are both classified within the β-herpesvirus subfamily. The role of CD317 in HHV-6 infection has not been previously investigated. In this study, we found that (i) HHV-6 infection induces CD317 expression, which in turn restricts HHV-6 infection, (ii) type I interferon stimulation induces CD317 expression, thereby inhibiting HHV-6 infection, (iii) the HHV-6 envelope glycoprotein O (gO) interacts with CD317, leading to gO degradation, and (iv) CD317 is incorporated into HHV-6 virions. This work represents the first report elucidating the role of CD317 in HHV-6 infection and reveals a novel function of gO in this process. IMPORTANCE: Upon stimulation with type I interferon, hundreds of interferon-stimulated genes (ISGs) are induced to express. For an individual virus, it is crucial to identify and analyze the key ISGs. Here, we discovered that CD317 is one of the key ISGs that restrict HHV-6 infection. While CD317 is well known for its ability to inhibit the release of progeny virions, we have revealed a novel role for CD317 in restricting HHV-6 infection by inhibiting viral entry. Additionally, we found that CD317 interacts with HHV-6 glycoprotein O (gO), a protein of unknown function, leading to the proteasomal degradation of gO. This finding may provide valuable clues for further analysis of gO's function.

Indexed as

Herpesvirus 6, HumanPlatelet Membrane GlycoproteinsRoseolovirus InfectionsHEK293 CellsHost-Pathogen InteractionsHumansInterferon Type IViral Envelope ProteinsInterferon Type IPlatelet Membrane GlycoproteinsViral Envelope ProteinsCD317gOHHV-6

Identifiers

PMID40552817
PMCPMC12282140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.